Marcello Cottini, Carlo Lombardi
Allergy and Pneumology Outpatient Clinic, Bergamo, Italy.
Departmental Unit of Allergology, Immunology & Pulmonary Diseases, Fondazione Poliambulanza, Via Bissolati, 57, 25124 Brescia, Italy.
Asthma Res Pract. 2016 Aug 12;2:11. doi: 10.1186/s40733-016-0026-6. eCollection 2016.
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and a variable course associated with various underlying mechanisms that can differ between individuals. Patients with asthma can therefore exhibit different phenotypes, a term used to define the observable characteristics of an organism resulting from the interaction between its genetic makeup and the environment. The heterogeneity of asthma has received a large amount of attention in the last few years in order to better tailor treatment according to the different clinical and biological phenotypes of the disease. Specific asthma phenotypes may require an approach to treatment sometimes different from that recommended by current guidelines, so a personalized approach to asthma pharmacotherapy is recommended. Growing evidence suggests that leukotrienes play an important role in the pathogenesis of bronchial asthma. The mechanisms of action of leukotriene-receptor antagonists theoretically predict a good response in some asthma "phenotypes".In this article we have performed an analysis of the recent literature (controlled clinical trials and real-life studies) about a possible selective intervention with Montelukast in specific asthma phenotypes.
哮喘是一种异质性疾病，通常以慢性气道炎症和与个体间可能不同的各种潜在机制相关的可变病程为特征。因此，哮喘患者可能表现出不同的表型，这一术语用于定义生物体由于其基因组成与环境之间的相互作用而产生的可观察特征。为了根据该疾病不同的临床和生物学表型更好地调整治疗方案，哮喘的异质性在过去几年中受到了大量关注。特定的哮喘表型有时可能需要一种与当前指南推荐的方法不同的治疗方法，因此推荐采用个性化的哮喘药物治疗方法。越来越多的证据表明，白三烯在支气管哮喘的发病机制中起重要作用。白三烯受体拮抗剂的作用机制从理论上预测在某些哮喘“表型”中会有良好反应。在本文中，我们对最近关于孟鲁司特在特定哮喘表型中可能的选择性干预的文献（对照临床试验和实际研究）进行了分析。
